For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Bind Biosciences, Inc.

USPTO Granted Patents = 12

% Expired Patents = 50.0

EPO Patents = 1

Forward Citations = 758

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

Stephen E Zale (9 out of 50 patents)

Greg Troiano (7 out of 41 patents)

Mir Mukkaram Ali (7 out of 27 patents)

4. James I Wright (5 out of 59 patents)

5. Jeff Hrkach (4 out of 17 patents)

6. Young-Ho Song (2 out of 19 patents)

7. Christina Van Geen Hoven (2 out of 13 patents)

8. Michael Figa (2 out of 9 patents)

9. Abhimanyu Sabnis (2 out of 9 patents)

10. David Dewitt (1 out of 10 patents)

11. Luis Alvarez De Cienfuegos (1 out of 1 patent)

12 patents: Sort by Forward Citations

1. 8846077 - High throughput fabrication of nanoparticles (2014-09-30),

2. 8734846 - Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles (2014-05-27),

3. 8420123 - Drug loaded polymeric nanoparticles and methods of making and using same (2013-04-16),

4. 8357401 - Stable formulations for lyophilizing therapeutic particles (2013-01-22),

5. 8318211 - Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same (2012-11-27),

6. 8318208 - Drug loaded polymeric nanoparticles and methods of making and using same (2012-11-27),

7. 8293276 - Drug loaded polymeric nanoparticles and methods of making and using same (2012-10-23),

8. 8273363 - Cancer cell targeting using nanoparticles (2012-09-25),

9. 8246968 - Cancer cell targeting using nanoparticles (2012-08-21),

10. 8236330 - Cancer cell targeting using nanoparticles (2012-08-07),

11. 8211473 - Stable formulations for lyophilizing therapeutic particles (2012-07-03),

12. 8206747 - Drug loaded polymeric nanoparticles and methods of making and using same (2012-06-26),

Bind Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for the treatment of cancer. Their proprietary drug development platform enables the design and production of Accurins, which are particle-based targeted therapeutics that enhance the concentration of drugs at the site of disease. Through their innovative technology, Bind Biosciences aims to improve patient outcomes and change the way cancer is treated.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

12 Patents

#202 in Cambridge, MA

#1,543 in Massachusetts

#25,496 in US

#48,036 in the World

Cambridge, MA, United States of America

Bind Biosciences, Inc.

Forward Citations = 758

11 inventors:

Stephen E Zale (9 out of 50 patents)

Greg Troiano (7 out of 41 patents)

Mir Mukkaram Ali (7 out of 27 patents)

4. James I Wright (5 out of 59 patents)

5. Jeff Hrkach (4 out of 17 patents)

Please report any incorrect information to [email protected]

Loading…